Belated Good News: Merck Wins Accelerated Approval In Certain Triple Negative Breast Cancers

The Keytruda® juggernaut marches onward, allowing Merck a consistent, exceedingly high revenue franchise, from which to fund partnerships in other worthwhile, high burden arenas, like HIV and COVID-19.

In truth, this news came out earlier this week, but there were sweet surprises last evening, so I’m just getting to it over coffee this morning. Here’s the bit:

. . .The FDA granted accelerated approval to pembrolizumab combined with chemotherapy for treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1. . . .

As ever, Merck is very well positioned — to once again be the world’s most admired company, as the third decade of the 21st Century opens in a few weeks (as it was, in the middle to late decades of the last century).

We remain hopeful, open and smiling here — for a rekindling of that auspicious stature, in relation to the world at large, and specific portions of her precious human cargo. So, onward!


There are no comments on this post.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: